Corrigendum to “Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554” [Bioorg. Med. Chem. 19 (2011) 4482–4498]

Bioorganic & Medicinal Chemistry 19 (2011) 5742

Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry journal homepage: www.elsevier.com/locate/bmc

Corrigendum

Corrigendum to ‘‘Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554’’ [Bioorg. Med. Chem. 19 (2011) 4482–4498] Hironobu Maezaki a,⇑, , Yoshihiro Banno a, , Yasufumi Miyamoto a, Yusuke Moritoh a, Tomoko Asakawa a, Osamu Kataoka a, , Koji Takeuchi a, Nobuhiro Suzuki a, Koji Ikedo a, Takuo Kosaka a, Masako Sasaki a, Shigetoshi Tsubotani a, Akiyoshi Tani a, Miyuki Funami a,à, Yoshio Yamamoto a, Michiko Tawada a, Kathleen Aertgeerts b, Jason Yano b, Satoru Oi a,à a b

Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohomachi 2-chome, Yodogawa-ku, Osaka 532-8686, Japan Takeda San Diego, Inc., 10410, Science Center Drive, San Diego, CA 92121, USA

The name of Yusuke Moritoh mistakenly appeared as Yuusuke Moritou in the author line. The correct author line appears above.

DOI of original article: 10.1016/j.bmc.2011.06.032

⇑ Corresponding author. Tel.: +81 466 32 1106; fax: +81 466 29 4449.   à

E-mail address: [email protected] (H. Maezaki). Present address: 26-1, Muraoka-higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan. Present address: Pharmaceutical Production Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohomachi 2-chome Yodogawa-ku, Osaka 532-8686, Japan.

0968-0896/$ - see front matter Ó 2011 Elsevier Ltd. All rights reserved. doi:10.1016/j.bmc.2011.07.025